453 research outputs found
Recommended from our members
Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
BACKGROUND: Sunitinib prolongs progression-free survival (PFS) in patients with advanced pancreatic neuroendocrine tumours (pNET). Response Evaluation Criteria in Solid Tumors (RECIST)-defined partial responses (PR; classically defined as ⩾30% size decrease from baseline) are infrequent.
METHODS: Individual data of pNET patients from the phase II [NCT00056693] and pivotal phase III [NCT00428597] trials of sunitinib were analysed in this investigator-initiated, post hoc study. The primary objective was to determine the optimal RECIST (v.1.0) response cut-off value to identify patients who were progression-free at 11 months (median PFS in phase III trial); and the most informative time-point (highest area under the curve (AUC) by receiver operating characteristic (ROC) analysis and logistic regression) for prediction of benefit (PFS) from sunitinib.
RESULTS: Data for 237 patients (85 placebo; 152 sunitinib (n=66.50 mg \u274-weeks on/2-weeks off\u27 schedule; n=86 \u2737.5 mg continuous daily dosing (CDD)\u27)) and 788 scans were analysed. The median PFS for sunitinib and placebo were 9.3 months (95% CI 7.6-12.2) and 5.4 months (95% CI 3.5-6.01), respectively (hazard ratio (HR) 0.43 (95% CI 0.29-0.62); P
CONCLUSIONS: A 10% reduction within marker lesions identifies pNET patients benefiting from sunitinib treatment with implications for maintenance of dose intensity and future trial design
Plasma inflammatory cytokines and survival of pancreatic cancer patients.
OBJECTIVES: Inflammation and inflammatory conditions have been associated with pancreatic cancer risk and progression in a number of clinical, epidemiological, and animal model studies. The goal of the present study is to identify plasma markers of inflammation associated with survival of pancreatic cancer patients, and assess their joint contribution to patient outcome.
METHODS: We measured circulating levels of four established markers of inflammation (C-reactive protein (CRP), interleukin-6 (IL-6), soluble tumor necrosis factor receptor type II (sTNF-RII), and macrophage inhibitory cytokine-1 (MIC-1)) in 446 patients enrolled in an ongoing prospective clinic-based study. Hazard ratios (HRs) and 95% confidence intervals (CI) for death were estimated using multivariate Cox proportional hazards models.
RESULTS: Overall mortality was significantly increased in patients in the top quartile of CRP (HR = 2.52, 95% CI: 1.82-3.49), IL-6 (HR = 2.78, 95% CI: 2.03-3.81), sTNF-RII (HR = 2.00, 95% CI: 1.46-2.72), and MIC-1 (HR = 2.53, 95% CI: 1.83-3.50), compared to those in the bottom quartile (P-trend
CONCLUSION: Individual elevated plasma inflammatory cytokines are associated with significant and dramatic reductions in pancreatic cancer patient survival. Furthermore, we observed an independent combined effect of those cytokines on patient survival, suggesting that multiple inflammatory pathways are likely involved in PDAC progression. Future research efforts to target the inflammatory state using combination strategies in pancreatic cancer patients are warranted
imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management
The complexity of the clinical management of neuroendocrine neoplasia (NEN) is
exacerbated by limitations in imaging modalities and a paucity of clinically
useful biomarkers. Limitations in currently available imaging modalities
reflect difficulties in measuring an intrinsically indolent disease,
resolution inadequacies and inter-/intra-facility device variability and that
RECIST (Response Evaluation Criteria in Solid Tumors) criteria are not optimal
for NEN. Limitations of currently used biomarkers are that they are secretory
biomarkers (chromogranin A, serotonin, neuron-specific enolase and
pancreastatin); monoanalyte measurements; and lack sensitivity, specificity
and predictive capacity. None of them meet the NIH metrics for clinical usage.
A multinational, multidisciplinary Delphi consensus meeting of NEN experts (n
= 33) assessed current imaging strategies and biomarkers in NEN management.
Consensus (>75%) was achieved for 78% of the 142 questions. The panel
concluded that morphological imaging has a diagnostic value. However, both
imaging and current single-analyte biomarkers exhibit substantial limitations
in measuring the disease status and predicting the therapeutic efficacy.
RECIST remains suboptimal as a metric. A critical unmet need is the
development of a clinico-biological tool to provide enhanced information
regarding precise disease status and treatment response. The group considered
that circulating RNA was better than current general NEN biomarkers and
preliminary clinical data were considered promising. It was resolved that
circulating multianalyte mRNA (NETest) had clinical utility in both diagnosis
and monitoring disease status and therapeutic efficacy. Overall, it was
concluded that a combination of tumor spatial and functional imaging with
circulating transcripts (mRNA) would represent the future strategy for real-
time monitoring of disease progress and therapeutic efficacy
European integration at the crossroads: Democratic deepening for stability, solidarity and social justice. EuroMemorandum 2012
European integration at the crossroads: Democratic deepening for stability, solidarity and social justice. EuroMemorandum 2012
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Methods We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was progression-free survival. Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile. The final analysis of overall survival will be conducted in the future as specified in the protocol; a prespecified interim analysis of overall survival was conducted and is reported here. Results At the data-cutoff date for the primary analysis, the estimated rate of progression-free survival at month 20 was 65.2% (95% confidence interval [CI], 50.0 to 76.8) in the 177Lu-Dotatate group and 10.8% (95% CI, 3.5 to 23.0) in the control group. The response rate was 18% in the 177Lu-Dotatate group versus 3% in the control group (P<0.001). In the planned interim analysis of overall survival, 14 deaths occurred in the 177Lu-Dotatate group and 26 in the control group (P=0.004). Grade 3 or 4 neutropenia, thrombocytopenia, and lymphopenia occurred in 1%, 2%, and 9%, respectively, of patients in the 177Lu-Dotatate group as compared with no patients in the control group, with no evidence of renal toxic effects during the observed time frame. Conclusions Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim analysis; confirmation will be required in the planned final analysis. Clinically significant myelosuppression occurred in less than 10% of patients in the 177Lu-Dotatate group. (Funded by Advanced Accelerator Applications; NETTER-1 ClinicalTrials.gov number, NCT01578239 ; EudraCT number 2011-005049-11
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and
well tolerated in the phase 3 TELESTAR study in patients with carcinoid
syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on
somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the
safety and efficacy of telotristat ethyl in patients with CS (diarrhea,
flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic
acid (u5-HIAA)) with <4 BMs/day on SSAs (or ≥1 symptom or ≥4 BMs/day if not on
SSAs) during a 12-week double-blind treatment period followed by a 36-week
open-label extension (OLE). The primary safety and efficacy endpoints were
incidence of treatment-emergent adverse events (TEAEs) and percent change from
baseline in 24-h u5-HIAA at week 12. Patients (N = 76) were randomly assigned
(1:1:1) to receive placebo or telotristat ethyl 250 mg or 500 mg 3 times per
day (tid); 67 continued receiving telotristat ethyl 500 mg tid during the OLE.
Through week 12, TEAEs were generally mild to moderate in severity; 5
(placebo), 1 (telotristat ethyl 250 mg) and 3 (telotristat ethyl 500 mg)
patients experienced serious events, and the rate of TEAEs in the OLE was
comparable. At week 12, significant reductions in u5-HIAA from baseline were
observed, with Hodges–Lehmann estimators of median treatment differences from
placebo of −54.0% (95% confidence limits, −85.0%, −25.1%, P < 0.001) and
−89.7% (95% confidence limits, −113.1%, −63.9%, P < 0.001) for telotristat
ethyl 250 mg and 500 mg. These results support the safety and efficacy of
telotristat ethyl when added to SSAs in patients with CS diarrhea
(ClinicalTrials.gov identifier: Nbib2063659)
Neuroendocrine carcinoma arising in soft tissue: three case reports and literature review
<p>Abstract</p> <p>Background</p> <p>Neuroendocrine tumours (NET) are tumours arising from neuroendocrine cells of neural crest origin. They are characterised by the presence of neurosecretory granules which react positively to silver stains and to specific markers including neuron specific enolase, synaptophysin and chromogranin. Metastasis to the skin occurs infrequently but primary soft tissue NET is excessively rare.</p> <p>Case presentation</p> <p>We report our experience with 3 such cases. In the first case, the NET originated in muscle and was treated with wide surgical excision and adjuvant radiotherapy. The second case presented as a subcutaneous mass in the foot and the tumour was positive on <sup>123</sup>I mIBG scan. She has had prolonged recurrence-free survival following primary hypo-fractionated radiotherapy. In the third case, a cutaneous nodule proved to be a NET and at surgery, lymph node disease was present. He has remained disease-free after surgical excision without the need for external beam radiotherapy.</p> <p>Conclusion</p> <p>These tumours appear to have a good prognosis. Complete excision offers potentially curative treatment. Adjuvant radiotherapy may be helpful when the tumour margin is narrow. For patients with unresectable disease or where surgery would not be appropriate, radiotherapy appears to be an effective therapeutic option.</p
Development of emodepside as a possible adulticidal treatment for human onchocerciasis-The fruit of a successful industrial-academic collaboration
Current mass drug administration (MDA) programs for the treatment of human river blindness (onchocerciasis) caused by the filarial worm Onchocerca volvulus rely on ivermectin, an anthelmintic originally developed for animal health. These treatments are primarily directed against migrating microfilariae and also suppress fecundity for several months, but fail to eliminate adult O. volvulus. Therefore, elimination programs need time frames of decades, well exceeding the life span of adult worms. The situation is worsened by decreased ivermectin efficacy after long-term therapy. To improve treatment options against onchocerciasis, a drug development candidate should ideally kill or irreversibly sterilize adult worms. Emodepside is a broad-spectrum anthelmintic used for the treatment of parasitic nematodes in cats and dogs (Profender and Procox). Our current knowledge of the pharmacology of emodepside is the result of more than 2 decades of intensive collaborative research between academia and the pharmaceutical industry. Emodepside has a novel mode of action with a broad spectrum of activity, including against extraintestinal nematode stages such as migrating larvae or macrofilariae. Therefore, emodepside is considered to be among the most promising candidates for evaluation as an adulticide treatment against onchocerciasis. Consequently, in 2014, Bayer and the Drugs for Neglected Diseases initiative (DNDi) started a collaboration to develop emodepside for the treatment of patients suffering from the disease. Macrofilaricidal activity has been demonstrated in various models, including Onchocerca ochengi in cattle, the parasite most closely related to O. volvulus. Emodepside has now successfully passed Phase I clinical trials, and a Phase II study is planned. This Bayer–DNDi partnership is an outstanding example of “One World Health,” in which experience gained in veterinary science and drug development is translated to human health and leads to improved tools to combat neglected tropical diseases (NTDs) and shorten development pathways and timelines in an otherwise neglected area
- …